In an investigation, Thapa et al.140applied a PEGylated lipid bilayer‐wrapped nano‐GO containing doxorubicin coupled with rapamycin, an inhibitor of the cell survival pathways PI3K/Akt/mTOR, to reduce the resistance of cancer cells. The gene discussed is AKT1; the disease is cancer.